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Serum lactate dehydrogenase (LDH) is used in diagnosing many diseases and is significantly determined by genetic factors. Three
genes coding for LDH isoenzymes were mapped to chromosome 11q15 and 12p12. We used 330 Framingham Heart Study largest
families for microsatellite linkage scan and 100K SNPs association scan to determine quantitative trait loci of LDH level. We
estimated the heritability at 41%. Our genome-wide linkage analysis yielded several chromosomal regions, other than 11q and
12p, with LOD scores between 1 and 2.5. None of the 100K SNPs with a P-value < 10-4 in our genome-wide association study was
close to the chromosomal regions where the LDH genes reside. Our study demonstrated a strong genetic effect on the variation of
LDH levels. There may not be a single gene with a large effect, instead may be several genes with small effects in controlling the
variation of serum LDH. Those genes may be located on chromosomal regions that differ from where the genes encoding LDH
isoenzymes reside.
1. Introduction
LDH is a cytoplasmatic enzyme found in almost all body
tissues. A small amount of the enzyme exists in the blood.
When cells are damaged or destroyed, they release LDH
into the bloodstream and cause blood levels to rise. LDH
is used in diagnosing heart, liver, muscle, lung diseases, and
testicular cancer. Its sensitivity and specificity in helping to
diagnose acute myocardial infarction are very high [1].
The enzyme is composed of 4 peptide chains of 2 types,
A and B. A is encoded by LDH A gene and predominant in
muscle, and B by LDH B gene predominant in the heart.
Five different combinations of A and B compose five LDH
isoenzymes: LDH1 (A4), LDH2 (A3B), LDH3 (A2B2), LDH4
(AB3), and LDH5 (B4). While all of the five isoenzymes are
represented in total serum LDH; LDH2makes up the greatest
percentage. In addition, there is homotetrameric LDH C
isoenzyme, encoded by the LDH C gene, found only in
mature testes and spermatozoa in humans. The LDH A and
C genes are syntenic on human chromosome 11q15 [2, 3]
while the LDH B gene maps to chromosome 12p12 [4].
Family studies have shown that serum LDH variation is
significantly determined by genetic factors with heritability
estimate as 50% [5]. So far, no genome-wide linkage or
association studies on serum levels of LDH have been
reported. We carried out a 10 cm genome-wide linkage
analysis and an Affymetrix HumanGeneChip 100K genome-
wide association study for quantitative trait loci of serum
LDH level in a community-based Caucasian cohort, the
Framingham Heart Study.
2. Subjects andMethods
The Framingham Heart Study, a population-based study,
began in 1948 with the recruitment of 5209 residents
aged 28–62 years (mean age 44.1) from Framingham,
Massachusetts [6]. The participants have undergone biennial
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examinations since the study began. In 1971, the Framing-
ham Offspring Study [7] was started, in part, to evaluate
the genetic components of cardiovascular disease etiology.
In total, 5124 subjects aged 5–70 years (mean age 36.3)
including the offspring of the original cohort and the spouses
of the offspring were recruited. The offspring cohort has been
examined every four years (except the first two examinations
with eight years intervening). Within the study, the 330
largest extended families were selected and genotyped with
a 10 cm density microsatellite marker and the Affymetrix
Human GeneChip 100K genome-wide scans. The number
of subjects with microsatellite genotyped was 1702 and
with the 100K SNPs genotyped was 1343. A recent study
reported no evidence of major population substructure in
the FraminghamHeart Study [8]. LDHwasmeasured during
the first (1971–1975) and second (1980–1983) examinations
of the offspring. Our analysis was limited to the first
examination, since far fewer individuals have serum LDH
measured in the second examination.
Total LDH was measured by kinetic method using Dow
UV LDH-Reagent Kit. Weight was measured with the subject
in light clothing and shoes off. Laboratory measurements
were made on 12 hours fasting venous blood samples
that were collected in tubes containing 0.1% EDTA. Lipid
determinations were performed at the Framingham Heart
Study laboratory, which participates in the Standardization
Program of the Centers for Disease Control. All subjects
provided informed consent prior to each clinic visit, and
the examination protocol was approved by the Institutional
Review Board at Boston Medical Center (Boston, MA).
The clinical and laboratory methods have been detailed
elsewhere [5].
2.1. Genotyping Methods. For the microsatellite genotyping,
genomic DNA was isolated from nucleated blood cells. DNA
samples were sent to theMarshfieldMammalian Genotyping
Service (http://research.marshfieldclinic.org/genetics/). At
an average of 10 cm density, 399 microsatellite markers
(Screening Set 9) [9] covered the genome with an average
marker heterozygosity of 0.77. The genotyping data were
cleaned in two steps. First, the sib-kin program in Aspex
(ftp://lahmed.standord.edu/pub/aspex/index.html) was used
to verify family relationships based on all markers available.
Second, the GENTEST program, as a precursor of INFER,
created by Southwest Foundation for Biomedical Research
(http://www.sfbr.org/sfbr/public/software/software.html),
was used to identify and eliminate additional genotype
inconsistencies. When inconsistencies were found, the
genotyping values in all members of the nuclear family were
set to missing.
For the Affymetrix 100K SNPs genotyping, the details
are provided in [10]. In summary, SNPs on the Affymetrix
Human GeneChip 100K (n = 112,990 autosomal SNPs) were
genotyped in a sample of 1343 individuals from 330 families.
SNPs with minor allele frequency <10% or call rate <80% or
Hardy-Weinberg equilibrium P-value <.001 were excluded,
leaving 70591 SNPs for analysis, criteria set by the Framing-
ham Heart Study for the Affymetrix 100K SNPs association
genome-wide scans [11]. The 100K SNPs data are publicly
available through dbGaP (http://www.ncbi.nlm.nih.gov/gap)
under Framingham SHARe project.
2.2. Statistical Methods
2.2.1. Genome-Wide Linkage Analysis. Variation in LDH
from known factors was identified and removed by
regression modeling incorporated in SOLAR [12–14], to
enhance the ability of linkage analysis to detect genetically
determined variation using a maximum-likelihood-based
variance decomposition method. The covariates selected
(P < .05) and incorporated into both the heritability estima-
tion and the linkage analyses were age, sex, height, weight,
high density lipoprotein cholesterol (HDL-C), and alkaline
phosphatase (ALP).
An estimate of heritability was obtained using the
variance-component method. Heritability is the proportion
of total phenotypic variation due to additive genetic effects,
after removing the variation attributable to covariates. The
variance component method analysis was also used for the
linkage analysis of LDH, adjusted for known covariates, using
the random microsatellite DNA markers covering the entire
genome. Marker allele frequencies were estimated from the
study participants and then used to estimate the proportion
of a single-point alleles shared identical by descent (IBD)
among all relative pairs. Multipoint IBDs were estimated
based on the singlepoint estimates by a regression approach
[13]. A likelihood ratio test was used to evaluate linkage by
comparing a purely polygenic model (without consideration
of genetic marker information) to a model that incorporates
IBD information at the marker. The LOD score was the log
(base 10) of the ratio of the likelihoods of two models, purely
polygenic versus one that also included IBD information at
the marker.
Since the variance-component method is based on the
assumption of a multivariate normal distribution, violations
of this assumption may result in inaccurate results [14–16].
We found that LDH had high kurtosis and thus used an LOD
score adjustment method implemented in SOLAR to ensure
more reliable results. A fully informative marker linked to
the trait studied was simulated. The IBD information for this
marker was calculated, and then linkage analysis to the trait
was performed. The LOD score adjustment process [15, 16]
regresses the observed LOD scores from simulation (10,000
replicates) on the expected LOD scores for a multivariate
normal trait to obtain a correction factor for the LOD scores
from the analyses of the observed trait. This method provides
robust LOD scores for data with nonnormal distributions.
2.2.2. Genome-Wide Association Study. One individual from
each family was randomly selected for the Hardy-Weinberg
equilibrium (HWE) test using a chi-squared statistic with
one degree of freedom. For each SNP, we modeled the log-
transformed trait value adjusted for the same covariates as
used in the linkage analysis. Trait values within each pedigree
were assumed to be correlated, while they were independent
between pedigrees. A special case of linear mixed effects
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Table 1: Characteristics of the 1603 individuals with LDH and
covariates used in the linkage analysis.
Variable Mean ± SD Range
LDH (mg/dl) 155.9 ± 34.7 55.0–600.0
Age (years) 32.7 ± 10.5 10–64
ALP∗ (mg/dl) 58.3 ± 17.8 16.0–98.0
Height (inchs) 66.2 ± 4.0 52.3–77.5
Weight (pound) 156.6 ± 34.6 54.0–281.0
HDL-C# (mg/dl) 50.4 ± 14.0 16.0–118.0
∗alkaline phosphatase.
#high density lipoprotein cholesterol.
model (LME) in SAS was used to fit the model with the
covariates and calculate the residual for each individual. The
following model was used for family i, Y = Xβ + , where Y
is a vector of log-transformed LDHs of subjects in the family,
and X contains covariates to adjust (age, sex, height, weight,
HDL-C, and ALP), which were treated as fixed effects. The
covariance matrix for Y in family i was unstructured. Once
the estimate of β was obtained, denoted as ̂β, we calculated
the residual for person j in family i with covariates Xij as
∗i j = Yij − Xiĵβ. Then, in the second stage, we modeled the
association between the residual and genetic effect by LME
given by ∗ = μ+βc(G)+, where the covariancematrix of ∗
was unstructured within each family and diagonal between
families, and c(G) was a coding for the genetic models
underlying the disease locus, which were defined as recessive,
additive, or dominant. For each genetic model, a P-value
was obtained. The smallest of the three P-values was used
to rank all SNPs. In genome-wide association studies, some
SNPs associated with common diseases have little additive
effect while there is strong deviation from Hardy-Weinberg
equilibrium, which indicates strong recessive or dominant
effects [17, 18]. These SNPs would not be detected using
the P-value only based on the additive model. Using the
minimum P-value to rank SNPs will be able to detect SNPs
with all three genetic models. Since the minimum P-value
is no longer a true p-value, we used the following threshold
values: if the minimum P-value is less than 5 × 10−7, the
association is regarded as strong, while if the minimum P-
value is between 5 × 10−7 and 1 × 10−5, the association is
moderate. No correction for multiple testing was given for
the minimum P-value.
3. Results
3.1. Genome-Wide Linkage Analysis. The total number of
individuals with measured LDH and with all covariates used
for the heritability estimates and linkage analysis in offspring
was 1603. The basic characteristics of the clinical covariates
of these individuals (about 50% male) are displayed in
Table 1. Of the 1603 individuals, 1260 had microsatellite
marker genotypes.
The skewness and kurtosis of LDH was 1.87 ± 0.04 and
13.92 ± 0.07, respectively. The heritability estimate for LDH,
after adjusting for the covariates, was 40.9 ± 6.4%. The
Table 2: Chromosomal regions in the genome scan withmultipoint
LODs ≥ 1.0.
Chromosome cm (Mbp) LOD score
3 55 (29) 1.03
4 195 (186) 2.01
7 51 (33) 1.08
8 37 (18) 2.25
9 164 (137) 2.41
19 91 (59) 1.24
20 96 (57) 1.28
proportion of variation due to all covariates included in the
model was approximately 5.8%.
From the multipoint linkage analysis of LDH, several
maximum LOD scores between 1 and 2.5 were observed on
different chromosomes (Table 2). The highest LOD score was
2.41 on chromosome 9.
3.2. Genome-Wide Association Study. After log-transformed,
only one individual’s LDH value, 1.74, was out of the range
of 5SD from the mean, 1.77–2.64. Since the value of 1.74
was so close to the lower bound of 1.77, we did not exclude
this individual from the association study and reanalyzed the
data. In the genome-wide association study, no SNP showed
strong association, while there were two SNPs, rs9318892 and
rs10518949, which showed moderate association. The top
ranked SNP on chromosome 13 had a minimum P-value of
7.1 × 10−7, while the second one on chromosome 15 had a
mini p = 1.6 × 10−7. There were 32 SNPs having a minimum
P < 10−4, Table 3. All SNPs within 60 kb of LDHA gene
(rs4237721, rs2279900, rs8018, rs3781640) and LDHB gene
(rs10505873, rs1677106, rs1677104, rs1030452, rs1012354)
have a P-value > .20.
4. Discussion
In our study, the heritability of LDH was estimated at
41% indicating that a substantial portion of the variation
in serum LDH was attributable to additive genetic factors.
This is consistent with a previous finding [5]. In the
linkage study, we identified several chromosomal regions
with LOD scores between 1 and 2.5. None of them are
located on the chromosomes where the genes encoding the
LDH isoenzymes reside. No obvious candidate genes were
found in those chromosomal regions. In the genome-wide
association study, no SNP with genome-wide significance
was observed. Furthermore, testing three models per SNP
in the genome-wise association study adds burden to the
multiple test and this is not reflected in the P-values in
Table 3. Among the top 32 SNPs with a P-values <10−4, none
of them were near the LDH structure genes, and none were
within the regions of linkage peaks. Similarly as in the linkage
analysis, no obvious candidate genes were found on those
chromosomal regions.
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Table 3: Top 32 SNPs associated with LDH levels with a minimum P-value < 10−4 by LME test.
SNP Chromosome Physical position cm P recessive P additive P dominant Minume P
rs9318892 13 82117408 64.375 7.08385E–07 4.61436E–06 0.0159389 7.084E–07
rs10518949 15 69415390 71.581 0.134216811 9.45936E–06 1.557E–06 1.557E–06
rs727614 15 51032409 46.056 0.000132039 1.28881E–05 0.0004033 1.289E–05
rs1953433 14 32515449 34.638 1.65253E–05 0.011049891 0.1025113 1.653E–05
rs1010154 13 29188260 18.909 2.06735E–05 0.001041981 0.0885699 2.067E–05
rs7716399 5 158083224 161.32 2.48992E–05 0.001732614 0.0504592 2.49E–05
rs1900451 10 55347706 75.028 0.085104884 7.70997E–05 2.999E–05 2.999E–05
rs722248 12 22258340 41.55 3.05871E–05 0.005615733 0.1632718 3.059E–05
rs1576305 10 83162789 103.389 0.036085304 3.15764E–05 6.928E–05 3.158E–05
rs10502525 18 24919668 54.364 0.014370952 0.000511018 3.286E–05 3.286E–05
rs7584028 2 117190012 126.113 3.37709E–05 7.68122E–05 0.0198111 3.377E–05
rs1493517 4 134829467 131.851 0.298266675 0.000672686 3.458E–05 3.458E–05
rs885813 1 21622380 48.53 0.057221322 0.000195121 3.493E–05 3.493E–05
rs2041980 17 63989613 89.283 4.36211E–05 0.027976619 0.2023116 4.362E–05
rs8030379 15 82381914 78.92 4.53895E–05 0.00011607 0.0199542 4.539E–05
rs9307696 4 134844616 131.86 4.88235E–05 0.001081816 0.3657347 4.882E–05
rs10504663 8 79031234 94.61 0.012473446 4.99754E–05 0.0001801 4.998E–05
rs9321611 6 137829536 138.685 0.882919264 0.000892122 5.233E–05 5.233E–05
rs463803 5 4320126 9.41 0.919049301 0.000981696 5.306E–05 5.306E–05
rs1389338 4 134829546 131.851 6.18458E–05 0.002386073 0.4999584 6.185E–05
rs723042 2 33453353 51.318 0.335052364 0.017567277 6.41E–05 6.41E–05
rs2365269 1 61772234 94.186 6.47241E–05 0.001204636 0.0673609 6.472E–05
rs10521232 17 13480529 32.75 6.91427E–05 0.000101251 0.0349411 6.914E–05
rs545833 1 165421598 185.51 0.000367903 7.08984E–05 0.004562 7.09E–05
rs10509003 10 55437628 75.145 0.001836912 7.09645E–05 0.0008584 7.096E–05
rs2274446 1 204640851 223.697 0.029912393 7.3719E–05 0.0001397 7.372E–05
rs1340682 1 80195427 107.56 0.233607102 0.000801941 7.815E–05 7.815E–05
rs10517702 4 160646045 157.99 7.84578E–05 0.167193446 0.2764248 7.846E–05
rs649395 6 16884305 32.62 7.88943E–05 0.000696352 0.6193636 7.889E–05
rs2061999 15 82373744 78.92 0.027938291 0.00020456 8.577E–05 8.577E–05
rs2135880 15 82380617 78.92 9.11851E–05 0.00022116 0.0268194 9.119E–05
rs2317948 1 55146464 80.565 0.112776442 0.000354101 9.779E–05 9.779E–05
A power study for linkage on the 330 Framing-
ham families with traits measured only in the Off-
spring Cohort, similar to our study, was performed using
SOLAR. The power was estimated to be 97%, 84%, and
62% to detect a QTL heritability of 30% using a LOD
score cut off of 1, 2, or 3, respectively, as significant
(http://www.framinghamheartstudy.org/). The results of the
simulation studies imply that this study sample only has
sufficient power to detect large QTL effects. A power
study for association on the same study population under
additive genetic model demonstrated 97%, 100%, 94%, and
77% power for SNP minor allele frequencies of 5%, 10%,
20%, and 30%, assuming 10% QTL heritability, the allele
frequency for the QTL to be 0.10, and the QTL and the
marker are in linkage disequilibrium (D′ = 1). The power
was calculated using PBAT, a software for the family-based
association test (the same Framingham website mentioned
above). Usually LME is expected to have higher power than
PBAT, since only heterozygous parents are informative for
a family-based study. The results of the simulation studies
imply that this study population may have good power
for linkage study. However, since the Affymetrix 100K
GeneChip has a mean marker distance of 26 kb, in most
situations, the genomic coverage may not be high enough
to reach the power mentioned above for association study
unless there is a major gene with a larger effect size in linkage
disequilibrium with the adjacent SNPs.
Although there is a strong genetic effect on the variation
of serum LDH levels, the results of both linkage and
association genome scans did not show evidence of a major
gene effect. Instead, there may be many genes with small
effects in controlling the variation of serum LDH levels.
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A limitation of this study is that our cohort is mostly
composed of Caucasians. Therefore, caution is advised in
extrapolating our results to other ethnicities.
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